D
David W. Bilheimer
Researcher at University of Texas Southwestern Medical Center
Publications - 67
Citations - 36848
David W. Bilheimer is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Familial hypercholesterolemia & LDL receptor. The author has an hindex of 44, co-authored 67 publications receiving 36714 citations. Previous affiliations of David W. Bilheimer include University of California, San Diego & The Rogosin Institute.
Papers
More filters
Journal ArticleDOI
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more
TL;DR: Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
Journal ArticleDOI
Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes: Phase Z of the A to Z Trial
James A. de Lemos,Michael A. Blazing,Stephen D. Wiviott,Eldrin F. Lewis,Keith A.A. Fox,Harvey D. White,Jean L. Rouleau,Terje R. Pedersen,Laura H. Gardner,Robin Mukherjee,Karen E. Ramsey,Joanne Palmisano,David W. Bilheimer,Marc A. Pfeffer,Robert M. Califf,Eugene Braunwald +15 more
TL;DR: Among patients with ACS, the early initiation of an aggressive simvastatin regimen resulted in a favorable trend toward reduction of major cardiovascular events and the trial did not achieve the prespecified end point.
Journal ArticleDOI
Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.
TL;DR: The current data suggest that mevinolin alone ormevinolin plus bile acid depletion (i.e., ileal bypass or colestipol therapy) decreases plasma LDL levels primarily by raising the number of LDL receptors and, thus, enhancing the removal of LDL from plasma.
Journal ArticleDOI
Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia.
TL;DR: It is concluded that a genetically determined deficiency of LDL receptors can be largely reversed by liver transplantation, underscoring the importance of hepatic LDL receptors in controlling the plasma level of LDL cholesterol in human beings.
Journal ArticleDOI
Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog
TL;DR: In this paper, the liver membranes from young beagle dogs were found to possess binding sites that resemble the low density lipoprotein (LDL) receptors originally described in cultured human fibroblasts.